Menu Close

Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma

Citation

Egolf, Laura E.; Vaksman, Zalman; Lopez, Gonzalo; Rokita, Jo Lynne; Modi, Apexa; Basta, Patricia V.; Hakonarson, Hakon; Olshan, Andrew F.; & Diskin, Sharon J. (2019). Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma. American Journal of Human Genetics, 105(3), 658-68. PMCID: PMC6731370

Abstract

Neuroblastoma is a cancer of the developing sympathetic nervous system. It is diagnosed in 600-700 children per year in the United States and accounts for 12% of pediatric cancer deaths. Despite recent advances in our understanding of this malignancy's complex genetic architecture, the contribution of rare germline variants remains undefined. Here, we conducted a genome-wide analysis of large (>500 kb), rare (<1%) germline copy number variants (CNVs) in two independent, multi-ethnic cohorts totaling 5,585 children with neuroblastoma and 23,505 cancer-free control children. We identified a 550-kb deletion on chromosome 16p11.2 significantly enriched in neuroblastoma cases (0.39% of cases and 0.03% of controls; p = 3.34 × 10(-9)). Notably, this CNV corresponds to a known microdeletion syndrome that affects approximately one in 3,000 children and confers risk for diverse developmental phenotypes including autism spectrum disorder and other neurodevelopmental disorders. The CNV had a substantial impact on neuroblastoma risk, with an odds ratio of 13.9 (95% confidence interval = 5.8-33.4). The association remained significant when we restricted our analysis to individuals of European ancestry in order to mitigate potential confounding by population stratification (0.42% of cases and 0.03% of controls; p = 4.10 × 10(-8)). We used whole-genome sequencing (WGS) to validate the deletion in paired germline and tumor DNA from 12 cases. Finally, WGS of four parent-child trios revealed that the deletion primarily arose de novo without maternal or paternal bias. This finding expands the clinical phenotypes associated with 16p11.2 microdeletion syndrome to include cancer, and it suggests that disruption of the 16p11.2 region may dysregulate neurodevelopmental pathways that influence both neurological phenotypes and neuroblastoma.

URL

http://dx.doi.org/10.1016/j.ajhg.2019.07.020

Reference Type

Journal Article

Journal Title

American Journal of Human Genetics

Author(s)

Egolf, Laura E.
Vaksman, Zalman
Lopez, Gonzalo
Rokita, Jo Lynne
Modi, Apexa
Basta, Patricia V.
Hakonarson, Hakon
Olshan, Andrew F.
Diskin, Sharon J.

Year Published

2019

Volume Number

105

Issue Number

3

Pages

658-68

PMCID

PMC6731370

Reference ID

13073